SciBase Secures First Payer Coverage in U.S. with Highmark
SciBase Holding AB announced its Nevisense technology has received its first positive medical policy from Highmark Blue Cross Blue Shield in the United States. This marks a significant commercial milestone.
Swedish medical technology company SciBase Holding AB has achieved a significant milestone in the U.S. market. The company announced Monday that its Nevisense technology has received its first positive payer coverage decision from Highmark Blue Cross Blue Shield, one of the largest Blue Cross Blue Shield organizations in the United States.
This decision represents a major turning point in SciBase's commercial strategy in the U.S., enabling the use of Nevisense to shift from a predominantly cash-pay model to covered care through a major private insurer. This removes one of the most significant barriers to broader clinical adoption of the technology.
SciBase has already demonstrated strong commercial momentum in the U.S. without widespread private payer reimbursement. The Highmark decision introduces a new growth driver to the existing business, expanding the number of dermatology practices and patients who can utilize Nevisense within a reimbursed model.
"This is a defining milestone for SciBase and an important step forward in the development of our U.S. business," said Pia Renaudin, CEO of SciBase. "Highmark coverage begins to remove one of the most important barriers to scale and creates the opportunity to reach a substantially larger portion of the U.S. market."